News from shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

10 Jun, 2016, 20:10 BST Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru

Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta ...


03 Jun, 2016, 13:00 BST Shire to Participate at Two Upcoming Investor Conferences

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will present at the Goldman Sachs 37th Annual Global...


03 Jun, 2016, 08:40 BST Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions

Combined company expected to deliver double-digit compound annual top-line growth with over $20 billion in annual revenues by 2020 Rare disease...


27 May, 2016, 07:00 BST Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...


29 Apr, 2016, 12:21 BST Shire Delivers Strong Q1 2016 Results with Double-digit Growth in Revenue and Non GAAP Earnings per ADS

Proposed combination with Baxalta on track with shareholder votes set for May 27 and closing anticipated in early June 2016 Shire plc ("Shire") (LSE: ...


27 Apr, 2016, 14:59 BST Shire to Participate at the Deutsche Bank 41st Annual Health Care Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will present at the Deutsche Bank 41st Annual Health Care...


18 Apr, 2016, 15:17 BST Shire plc (“Shire”) Publication of Circular, Notice of General Meeting and Prospectus and Directorate Change

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...


06 Apr, 2016, 19:37 BST Shire Comments on Recent US Treasury Notice

Proposed Combination with Baxalta on Track to Close in Mid-2016 Shire plc (LSE: SHP, NASDAQ: SHPG) acknowledges the US Treasury notice published on...


29 Mar, 2016, 12:18 BST Shire Wins Patent Trial Against Watson Concerning LIALDA®

LIALDA Patent Upheld and Extends through June 8, 2020 Shire plc (LSE: SHP, NASDAQ: SHPG) and its subsidiary, Shire Development LLC, announced today...


03 Mar, 2016, 16:00 GMT Developments to Income Access Share Arrangements - Elections for the Interim Dividend in Respect of the Six Months to December 31, 2015

Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") reminds shareholders of important developments relating to the Company's Income Access Share...


03 Mar, 2016, 14:00 GMT Shire to Participate at the Cowen 36th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the Cowen 36th Annual Healthcare...


11 Feb, 2016, 15:53 GMT Shire Delivers Record Full-year Revenue and Strong Double Digit Growth in Non GAAP Diluted Earnings per ADS

Transformational M&A achieved through NPS and Dyax acquisitions and the announced combination with Baxalta Positioned for future growth with most...


10 Feb, 2016, 22:24 GMT Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD Treatment for Children

This press release is intended for U.S. and EU audiences only. A separate press release has been prepared for use in Japan. With submission, Shire...


09 Feb, 2016, 14:00 GMT Shire Marks 30th Anniversary with Innovative Global Program to Benefit Children with Rare Diseases

Three-Year Initiative Supports Next Generation of Medical Geneticists and Enables Children to Take Part in Life-Changing Camp Experiences To mark the ...


04 Feb, 2016, 20:45 GMT U.S. FDA Acknowledges Receipt of Resubmission of Shire's New Drug Application for Lifitegrast for Dry Eye Disease in Adults

- New FDA action date of July 22, 2016 - Lifitegrast has the potential to be the only product approved in the U.S. in the past decade indicated for...


28 Jan, 2016, 14:47 GMT Shire plc Assigned Investment Grade Credit Ratings by Moody's and S&P

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has been assigned investment grade credit ratings by the world's two leading credit rating ...


25 Jan, 2016, 12:00 GMT Shire Resubmits New Drug Application for Lifitegrast to U.S. FDA

Resubmission includes positive data from OPUS-3, a Phase 3 efficacy and safety trial Company committed to advancing new treatment option to address...


22 Jan, 2016, 14:16 GMT Shire Completes Acquisition of Dyax

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has completed its acquisition of Dyax Corp. (NASDAQ: DYAX) in an all-cash transaction...


15 Dec, 2015, 07:00 GMT Shire to Present at 34th Annual J.P. Morgan Healthcare Conference

Enters 2016 with most robust clinical pipeline in its 30-year history, focused on rare diseases and specialty conditions Over 25 clinical development ...


24 Nov, 2015, 14:00 GMT Shire to Participate at the Piper Jaffray 27th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that Jeff Poulton, Chief Financial Officer, will participate in the Piper Jaffray 27th Annual...


27 Oct, 2015, 11:48 GMT Shire's OPUS-3 Phase 3 Trial with Lifitegrast Meets Primary and Key Secondary Endpoints, Significantly Reducing Patient-Reported Symptoms for Dry Eye Disease

Data to support lifitegrast FDA resubmission in Q1 2016; plans on track for potential 2016 launch The topline data showed OPUS-3, a phase 3 trial,...


23 Oct, 2015, 13:23 BST Shire Announces Third Quarter Earnings and Reiterates Full Year Guidance

Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months to September 30, 2015. Financial Highlights Q3 2015 Growth(1) Non...


17 Oct, 2015, 01:44 BST Shire Receives FDA Complete Response Letter for Lifitegrast NDA and Plans to Respond with OPUS-3 Trial

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) requested an additional clinical study as part of ...


13 Oct, 2015, 12:00 BST Shire's CINRYZE® (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection (AMR) in Patients Receiving Kidney Transplants

Shire continues to demonstrate commitment to delivering innovation in areas of unmet medical need Shire plc (LSE: SHP, NASDAQ: SHPG) today announced...


01 Oct, 2015, 13:00 BST Shire Announces Winners of Spotlight on Gaucher Film Contest to Mark International Gaucher Day

Shire plc (LSE: SHP, NASDAQ: SHPG) is pleased to announce the winner and runner up of the Spotlight on Gaucher film contest on the occasion of...